Neurocrine Biosciences
NBIX
$97.05
Share price
1.42%
Change (1 day)
3.55%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Revenue for Neurocrine Biosciences (NBIX)
Revenue in 2022 (TTM): $1.48 B
According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM) is $1.48 B. In 2021 the company made a revenue of $1.13 B an increase over the years 2020 revenue that were of $1.04 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Neurocrine Biosciences from 2001 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $1.48 B | 31.34% |
| 2021 | $1.13 B | 8.38% |
| 2020 | $1.04 B | 32.71% |
| 2019 | $0.78 B | 74.65% |
| 2018 | $0.45 B | 179.19% |
| 2017 | $0.16 B | |
| 2015 | $19.76 M | INF% |
| 2014 | N/A | -100% |
| 2013 | $2.91 M | -94.51% |
| 2012 | $53.14 M | -31.36% |
| 2011 | $77.41 M | 131.08% |
| 2010 | $33.5 M | 1034.47% |
| 2009 | $2.95 M | -25.71% |
| 2008 | $3.97 M | 224.75% |
| 2007 | $1.22 M | -96.88% |
| 2006 | $39.23 M | -68.33% |
| 2005 | $0.12 B | 45.45% |
| 2004 | $85.17 M | -38.76% |
| 2003 | $0.13 B | 670.73% |
| 2002 | $18.04 M | -56.25% |
| 2001 | $41.24 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $100.33 B | 6,639.50% | 🇺🇸 USA |
 AbbVie ABBV | $58.05 B | 3,799.64% | 🇺🇸 USA |
 Eli Lilly LLY | $28.54 B | 1,817.20% | 🇺🇸 USA |
 Repligen
RGEN | $0.80 B | -46.16% | 🇺🇸 USA |
 Athersys ATHX | $6.01 M | -99.60% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.28 B | -80.98% | 🇺🇸 USA |
 Palatin Technologies PTN | $2.88 M | -99.81% | 🇺🇸 USA |
 Royalty Pharma RPRX | $2.23 B | 50.28% | 🇬🇧 UK |